PEPG Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.780

Open

6.230

VWAP

6.50

Vol

1.31M

Mkt Cap

464.74M

Low

5.970

Amount

8.53M

EV/EBITDA(TTM)

--

Total Shares

68.75M

EV

316.28M

EV/OCF(TTM)

--

P/S(TTM)

--

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Show More

Events Timeline

(ET)

2026-03-04

20:00:00

Tech Stocks Rally, Micron Up 5.5%

2026-03-04

16:20:00

PepGen Announces Regulatory Updates on Freedom2 Trial

2026-03-04

16:20:00

PepGen 2025 FREEDOM Trial Data Impresses

2026-03-04

16:10:00

PepGen Inc Trading Halted, News Pending

2025-12-08 (ET)

2025-12-08

07:30:00

PepGen Appoints Joseph Vittiglio as Chief Business and Legal Officer

2025-11-12 (ET)

2025-11-12

07:31:58

PepGen reveals grant of patent for PGN-EDODM1

News

seekingalpha

10:11 AMseekingalpha

PinnedPepGen Reports Q4 2025 Earnings Beat with Strong Cash Position

seekingalpha

12:11 PMseekingalpha

PepGen Shares Drop After FDA Partially Halts Clinical Trial

Benzinga

11:02 AMBenzinga

Veeva Systems Reports Strong Q4 Results and Raises FY27 Guidance

Benzinga

10:03 AMBenzinga

PepGen Faces FDA Partial Hold on FREEDOM2 Trial Amid Regulatory Concerns

Newsfilter

2025-12-09Newsfilter

PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant

Benzinga

2025-12-08Benzinga

Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday

2 Analyst Rating

Wall Street analysts forecast PEPG stock price to rise

1 Buy

0 Hold

1 Sell

Hold

Current: 0.000

Low

3.00

Averages

11.50

High

20.00

Current: 0.000

Low

3.00

Averages

11.50

High

20.00

Oppenheimer

Oppenheimer

Outperform

initiated

$15

AI Analysis

2026-02-25

Reason

Oppenheimer

Oppenheimer

Price Target

$15

AI Analysis

2026-02-25

initiated

Outperform

Reason

Oppenheimer initiated coverage of PepGen with an Outperform rating and $15 price target. The firm notes PepGen is a clinical-stage myotonic dystrophy type 1 company employing a cell-penetrating peptide aiming to optimize drug delivery. Despite its best-in-class efficacy in DM1, PepGen has been under pressure due to concerns that kidney adverse events observed with its Duchenne muscular dystrophy program could potentially reemerge in DM1, Oppenheimer notes. Although kidney safety is a credible risk, the firm's analysis of safety data suggests the 10mg/kg dose can balance acceptable safety with potentially best-in-class efficacy.

Guggenheim

Debjit Chattopadhyay

Buy

maintain

$6 -> $7

2026-02-18

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$6 -> $7

2026-02-18

maintain

Buy

Reason

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on PepGen to $7 from $6 and keeps a Buy rating on the shares. The firm, which anticipates data from the FREEDOM2 5 mg/kg MAD cohort in March, cites its analysis of the FREEDOM2 outlook for increasing its price target, noting that its base case scenario assumes SI correction in the high teens.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PEPG

Unlock Now

Valuation Metrics

The current forward P/E ratio for PepGen Inc (PEPG.O) is -5.20, compared to its 5-year average forward P/E of -2.70. For a more detailed relative valuation and DCF analysis to assess PepGen Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.70

Current PE

-5.20

Overvalued PE

-1.17

Undervalued PE

-4.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.37

Current EV/EBITDA

-3.35

Overvalued EV/EBITDA

0.17

Undervalued EV/EBITDA

-2.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Daytrading Signale andern

Intellectia · 28 candidates

Price: $5.00 - $100.00Relative Vol: >= 1.80Moving Average Relationship: PriceAboveMA20Three Min Rate Of Change: >= 0.7%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Ondas Inc

4.53B

Venture Global Inc

27.96B

SoundHound AI Inc

3.63B

Viavi Solutions Inc

8.18B

Intellia Therapeutics Inc

1.82B

Lionsgate Studios Corp

2.61B

Whales Holding PEPG

BVF Partners L.P.

Vivo Capital, LLC

RA Capital Management, L.P.

Commodore Capital LP

Qatar Holding LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is PepGen Inc (PEPG) stock price today?

The current price of PEPG is 6.76 USD — it has increased 5.3

What is PepGen Inc (PEPG)'s business?

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

What is the price predicton of PEPG Stock?

Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is11.50 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is PepGen Inc (PEPG)'s revenue for the last quarter?

PepGen Inc revenue for the last quarter amounts to -18.65M USD, decreased -19.49

What is PepGen Inc (PEPG)'s earnings per share (EPS) for the last quarter?

PepGen Inc. EPS for the last quarter amounts to -19356000.00 USD, decreased -20.01

How many employees does PepGen Inc (PEPG). have?

PepGen Inc (PEPG) has 81 emplpoyees as of March 05 2026.

What is PepGen Inc (PEPG) market cap?

Today PEPG has the market capitalization of 464.74M USD.